## UNITED STATES SECURITIES AND EXCHANGE COMMISSION 22 April 2015

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

## KYTHERA Biopharmaceuticals, Inc.

File No. 1-35663 – CF# 32189

KYTHERA Biopharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 2, 2015.

Based on representations by KYTHERA Biopharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.20	through March 2, 2018
Exhibit 10.21	through March 2, 2018
Exhibit 10.22	through January 16, 2018

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary